Crafting the Pitch: Aligning the Golden Triangle

Transcript

SPEAKER_1: Last time we landed on this core tension — clinical rigor and compelling unit economics, both at once. So now I want to get into the actual pitch. Where does a founder start? SPEAKER_2: The starting point is understanding that a health tech pitch must show value to three stakeholders simultaneously — the patient, the provider, and the payer. That's the Golden Triangle, and it's what separates a fundable story from a stalled one. SPEAKER_1: Three audiences in one pitch. How does a founder keep that coherent without losing the thread? SPEAKER_2: Each corner has a different definition of value. Patients want better outcomes and less friction. Providers want tools that fit their workflow. Payers want lower costs and measurable results. A pitch that speaks to a single corner can stall — and here's the harder truth: the person writing the check often isn't experiencing the benefit. SPEAKER_1: So a founder might be selling to a hospital CFO, but the value lands with a nurse or a patient. That disconnect must create real confusion in the room. SPEAKER_2: It does, and it's one of the most common places pitches fall apart. The fix is making the customer crystal clear from slide one — who is paying, who is using, and why the problem is painful enough that someone will actually spend money to solve it. SPEAKER_1: Now, reimbursement keeps coming up. Why do investors care so much about it specifically? SPEAKER_2: Because reimbursement is the revenue engine. If a product isn't reimbursable, adoption depends on a health system absorbing the cost — a much harder sell. Investors view reimbursement strategy and regulatory strategy as closely linked. A go-to-reimbursement plan signals the founder understands how money actually flows in healthcare. SPEAKER_1: Reimbursement milestones can be easy to oversimplify, right? A lot of founders treat them as a finish line. SPEAKER_2: That's a real trap. Having a reimbursement pathway doesn't by itself guarantee adoption or revenue. Payers can still deny coverage or reimburse at rates that break the business model. For example, a startup can have strong clinical promise, but if it can't explain whether providers, employers, insurers, consumers, or public systems will pay, investors will see an incomplete revenue story. SPEAKER_1: Good example. What about workflow — why does a technically sound product fail if it doesn't fit how clinicians actually work? SPEAKER_2: Because adoption is the real product. A tool that adds three extra steps to a clinical visit gets abandoned, no matter how accurate it is. Providers are already stretched. The pitch must anticipate implementation friction — workflow changes, EHR integration, training time. If a founder can't explain how the product fits an existing clinical day, that's a red flag. SPEAKER_1: So the pitch needs both a clinical roadmap and a technical roadmap. What's the actual difference between the two? SPEAKER_2: The technical roadmap covers product development — features, integrations, infrastructure. The clinical roadmap covers evidence generation — pilot design, endpoints, peer-review pathways, regulatory milestones. Both are essential. Regulation affects the timeline, and that has to be in the story, not buried in an appendix. SPEAKER_1: And the evidence bar keeps rising as the company grows. A pilot isn't enough forever. SPEAKER_2: Exactly. The evidence bar can rise as the company moves from early validation toward enterprise contracts. Enterprise contracts often require a higher standard of proof than pilot programs. The financing ask needs to be tied to specific milestones — not just 'eighteen months of runway,' but 'eighteen months to complete a validated clinical study and sign two enterprise contracts.' That's a fundable story. SPEAKER_1: For everyone building their deck right now, what's the structural principle that ties all of this together? SPEAKER_2: The key idea is simplicity. The pitch must be simple enough that an investor can retell it accurately after the meeting — problem, solution, why it's meaningfully better than alternatives, how it creates value across the Golden Triangle, the reimbursement path, the team, and exactly what the capital will accomplish. Aligning patient, provider, and payer incentives isn't just good strategy. It's proof the business model can survive contact with the healthcare system.